Altogether, we propose that, depending on the domain targeted, mutations affect TRIO’s function in opposite ways and give rise to two seemingly diverse clinical syndromes: severe developmental delay and macrocephaly (spectrin variants) versus a milder developmental phenotype and microcephaly (GEFD1 variants). The gene discussed is TRIO; the disease is microcephaly.